Altimmune's Pemvidutide Shows Broad Metabolic Benefits in MASH Patients
Event summary
- 48-week IMPACT Phase 2b trial data show pemvidutide significantly reduced triglycerides (-23.7%) and total cholesterol (-15.4%) in MASH patients.
- Pemvidutide 1.8 mg treatment led to 7.5% weight loss, 3.0 kg/m² BMI reduction, and 5.3 cm waist circumference reduction.
- Safety profile maintained with only 1% of patients discontinuing due to adverse events.
- PERFORMA Phase 3 trial initiation planned for late 2026 to further evaluate pemvidutide's efficacy and safety.
The big picture
Altimmune's pemvidutide is positioning itself as a potential breakthrough therapy for MASH, addressing both liver disease and underlying metabolic drivers. The positive Phase 2b data reinforce the company's strategy of targeting multiple metabolic risk factors, which is critical given the high cardiovascular mortality rates in MASH patients. The upcoming Phase 3 trial will be pivotal in determining pemvidutide's long-term viability in a competitive landscape.
What we're watching
- Clinical Efficacy
- Whether pemvidutide's broad metabolic improvements can translate into long-term clinical benefits for MASH patients.
- Regulatory Pathway
- The pace at which Altimmune can advance pemvidutide through Phase 3 trials and potential regulatory approval.
- Market Positioning
- How Altimmune positions pemvidutide against existing and emerging therapies for MASH and other metabolic diseases.
Related topics